載入...
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-C...
Na minha lista:
| 發表在: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7730610/ https://ncbi.nlm.nih.gov/pubmed/33271901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21239163 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|